Overview

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP). In 75 patients diagnosed with PSP Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) who Completed Study GV1001-PSP-CL2-011.

Phase:

PHASE2

Details

Lead Sponsor:

GemVax & Kael

Treatments:

Saline Solution